Skip to main content Back to Top
Advertisement

2/7/2024

Naltrexone Tablets

Products Affected - Description

    • Naltrexone oral tablet, Accord, 50 mg, bottle, 30 count, NDC 16729-0081-10
    • Naltrexone oral tablet, Accord, 50 mg, bottle, 100 count, NDC 16729-0081-01
    • Naltrexone oral tablet, Avet Pharmaceuticals, 50 mg, bottle, 30 count, NDC 23155-0886-03
    • Naltrexone oral tablet, Avet Pharmaceuticals, 50 mg, bottle, 100 count, NDC 23155-0886-01
    • Naltrexone oral tablet, Sun Pharma, 50 mg, bottle, 30 count, NDC 47335-0326-83
    • Naltrexone oral tablet, Sun Pharma, 50 mg, bottle, 100 count, NDC 47335-0326-88
    • Naltrexone oral tablet, Tagi Pharma, 50 mg, bottle, 30 count, NDC 51224-0206-30
    • Naltrexone oral tablet, Tagi Pharma, 50 mg, bottle, 100 count, NDC 51224-0206-50

Reason for the Shortage

    • Accord did not provide a reason for the shortage.
    • Avet did not provide a reason for the shortage.
    • Mallinckrodt refuses to provide availability information.
    • Sun did not provide a reason for the shortage.
    • Tagi Pharma did not provide a reason for the shortage.
    • Information from a few additional suppliers is forthcoming.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Accord has naltrexone 50 mg tablets on intermittent back order and the company is releasing supplies as they become available.
    • Avet has naltrexone 50 mg tablets on back order and the company cannot estimate a release date.
    • Sun has naltrexone 50 mg tablets on back order and the company estimates a release date in late-March 2024.
    • Tagi Pharma has naltrexone 50 mg tablets on back order and the company estimates a release date in mid-February 2024.

Updated

Created February 7, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.